Navigation Links
Resolve Initiates Phase 2 Clinical Study in SLE
Date:7/16/2014

SEATTLE, July 16, 2014 /PRNewswire/ -- Resolve Therapeutics, LLC announced today the initiation of a multi-dose, one month phase 2 clinical study with its lead compound RSLV-132 in systemic lupus erythematosus (SLE).

Following the successful completion of it phase 1 single dose safety study with RSLV-132, Resolve recently initiated a phase 2 study in lupus patients.  The study will be conducted at multiple sites in the U.S., and will investigate four dose levels, with multiple doses being administered over one month.  The study is designed to establish biological proof-of-concept for RSLV-132.

RSLV-132 is a novel Fc fusion protein consisting of human RNase attached to the Fc portion of human IgG.  The goal of the therapy is to reduce the burden of circulating RNA-containing immune complexes which are thought to be the most proximal trigger of the systemic inflammation characteristic of SLE.  By eliminating the RNA cargo contained in circulating immune complexes the therapy is designed to prevent chronic activation of nucleic acid sensing toll like receptors (e.g. TLR7 and TLR8) and subsequent activation of the interferon inflammatory cascade.  Additional therapeutic benefit is thought to result from dampening B-cell activation, as well as mitigation of the direct tissue damage caused by immune complex deposition in key organs, such as the kidney and brain.

"We are thrilled to move RSLV-132 one step closer to the large number of SLE patients that are not well controlled with current therapy" commented James Posada, chief executive officer of Resolve Therapeutics.

About Resolve Therapeutics
Resolve Therapeutics is a privately held biotechnology company based in Seattle that is dedicated to helping patients with lupus through the development of its platform of targeted nuclease therapeutics.  In addition to the lead molecule, RSLV-132, the company is developing additional molecules that contain both RNase and DNase activities, which may also be useful in the treatment of lupus and other autoimmune diseases resulting from aberrant nucleic acid deposition.  Resolve is funded by a syndicate of venture capital firms including, New Science Ventures, WRF Capital, and Easton Capital.  For more information on the company please visit us at:  http://www.resolvebio.com

Contact:

James Posada, Ph.D., MBA
Chief Executive Officer
Resolve Therapeutics, LLC
(208) 876-4057
jp@resolvebio.com

Logo - http://photos.prnewswire.com/prnh/20140715/127341


'/>"/>
SOURCE Resolve Therapeutics, LLC
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. RSC New England Clinicians to Present at RESOLVE New England’s 20th Annual Conference on November 2nd, 2013
2. New nanomedicine resolves inflammation, promotes tissue healing
3. WMIS Supports Experts, Commits to Resolve Beta Amyloid Issues with CMS
4. BioFit Helps Lab Specifiers Resolve to Improve Worker Safety and Productivity in 2013 through Ergonomic Seating Use
5. Cellectricon Launches Dynaflow® Resolve System Enabling Novel Ion Channel Assays
6. Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
7. inVentiv Health Initiates Refinancing Transactions To Fund Continued Growth
8. EquitiesIQ Initiates Coverage of Alliqua, Inc.
9. OxThera Initiates Clinical Trial in Primary Hyperoxaluria
10. Empire Asset Management Company initiates coverage on INSPIRE MD with a Buy rating
11. Acacia Pharma Initiates Pivotal Phase 3 Studies with APD421 in Post-Operative Nausea & Vomiting (PONV)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... (PRWEB) , ... February 08, 2016 , ... ... p.m. , Location: Baruch S. Blumberg Institute at the Pennsylvania Biotechnology Center of ... Blumberg Institute and The Commonwealth Medical College (TCMC) will hold an open house ...
(Date:2/9/2016)... ... February 09, 2016 , ... Tunnell Consulting, Inc. announced that Frédéric ... he will focus on acquiring new accounts and work closely with existing Tunnell clients ... “Fred brings to our European clients more than 15 years of experience in the ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... Public Policy for the National Organization for Rare Disorders (NORD). Dorman will lead ... their voices are heard throughout the drug regulatory review process. , “Adding Diane ...
(Date:2/9/2016)... LONDON , February 9, 2016 ... replace paper and protect IP   E-WorkBook ... will be rolled out in Germany ... and protect valuable IP. Users will be able to search ... or experiment as part of the application, to boost collaboration ...
Breaking Biology Technology:
(Date:2/3/2016)... 3, 2016 ... the "Emotion Detection and Recognition Market ... Others), Software Tools (Facial Expression, Voice Recognition ... Regions - Global forecast to 2020" ... http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the addition ...
(Date:2/2/2016)... 2, 2016 Checkpoint Inhibitors for Cancer ... Are you interested in the future of ... checkpoint inhibitors. Visiongain,s report gives those predictions to ... national level. Avoid falling behind in data ... and revenues those emerging cancer therapies can achieve. ...
(Date:2/2/2016)... MOUNTAIN VIEW, Calif. , Feb. 2, 2016 ... diabetic retinopathy market, Frost & Sullivan recognizes US-based ... North America Frost & Sullivan Award for New ... technology provider in North America ... standard in the rapidly growing diabetic retinopathy market. ...
Breaking Biology News(10 mins):